Three-Pronged attack on tough breast cancer begins human testing
NCT ID NCT07134556
Summary
This trial is testing a new combination of three drugs as the first treatment for people with advanced triple-negative breast cancer that tests positive for a marker called PD-L1. The goal is to see if the combination is safe and can shrink tumors and control the cancer. It will enroll about 25 adults who have not yet received treatment for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.